Core 2 O-glycans terminated with sialyl-Lewis x (sLe X :Siaα2-3Galβ1-4(Fucα1-3)GlcNAc) are functionally important oligosaccharides that confer particular macromolecules with high affinity glycan ligands for the selectin family. To date, antibodies that recognize these structures on leukocytes have not been described. We characterize such a monoclonal antibody (mAb) here (CHO-131, mouse IgM). The binding specificity of CHO-131 was directly examined using synthetic
indicates C2GnT activity and demonstrates that CLA T cells are heterogeneous based on the glycan structures they synthesize. These findings support evidence that differential C2GnT activity results in T cell subsets that express ligands for E-selectin, P-selectin, or both. walch003@umn.edu only.
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Introduction
The three members of the selectin family facilitate accumulation and rolling on the blood vessel wall of lymphocytes in secondary lymphoid organs and of leukocytes at sites of inflammation.
L-selectin (CD62L) is expressed by leukocytes, E-selectin (CD62E) is expressed by activated endothelial cells, and P-selectin (CD62P) is expressed by activated endothelial cells and activated platelets 1 . The selectins are Ca +2 -dependent lectins that bind discrete glycan structures on particular macromolecules 1, 2 . The leukocyte-expressed sialomucin, P-selectin glycoprotein ligand-1 (PSGL-1, CD162) is one such macromolecular ligand that is recognized by P-selectin 3 , E-selectin [4] [5] [6] [7] , and Lselectin 8, 9 .
The glycan modifications of PSGL-1 that are responsible for high affinity binding by Pselectin have been extensively examined and consist of sialylated and fucosylated, core 2 branched O-glycans 3 . These glycans are not sulfated in contrast to particular L-selectin glycan ligands expressed by endothelial cells 1 . Instead, PSGL-1 contains sulfated tyrosine residues that are required for P-selectin binding [10] [11] [12] [13] [14] . PSGL-1 on myeloid cells possesses two major species of sialylated and fucosylated, core 2 O-glycans. Extended from the core 2 branch is a three N-acetyllactosamine repeat ) has been directly demonstrated to confer high affinity P-selectin binding by using glycosulfopeptides modeled after the N-terminus of human PSGL-1 that contain precise O-glycan structures synthesized on a specific threonine residue 14, 16 . Though all peripheral blood leukocytes express PSGL-1 3 , the post-translational glycan modifications that result in selectin ligands occur differentially and are synthesized by all neutrophils and a subset of lymphocytes, which preferentially home to sites of chronic inflammation in the skin 3, [17] [18] [19] [20] . Properly stimulated and peripheral blood effector/memory T cells in general express upregulated mRNA levels of α2,3-sialyltransferase-IV, α1,3-fucosyltransferase-VII (FucT-VII), and the O-glycan branching enzyme core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) 18, [21] [22] [23] . Recent findings indicate a distinct requirement for C2GnT in the synthesis of E-and P-selectin glycan ligands by stimulated T cells. Snapp et al. 24 have reported that Th1 cells derived from C2GnT -/-mice expressed E-selectin, but not P-selectin, glycan ligands. Moreover, E-selectin-binding Th1 cells For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From (CLA), in most cases using the monoclonal antibody (mAb) HECA-452 25, 26 . A limitation of antisLe X mAbs, however, is that their epitope does not indicate the functional activity C2GnT. Moreover, the sLe X antigen is distributed on numerous leukocyte cell surface macromolecules, including proteins containing N-and O-glycans as well as lipids 27 , and its detection does not directly indicate modification of sialomucins with P-selectin glycan ligands 17 .
We report here the structural elucidation and leukocyte distribution of the epitope for the anticarbohydrate mAb CHO-131. The antigenic specificity of CHO-131 was assessed using synthetic glycopeptides with precise glycan structures as well as transfected cell lines expressing specific glycosyltransferases. The CHO-131 epitope is shown to comprise C2-O-sLe only.
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Methods
Antibodies. The mAbs CSLEX-1 (mouse IgM) and HECA-452 (rat IgM), specific to the sLe X carbohydrate antigen, have been previously described 28, 29 . The mAbs PL1 (mouse IgG1), specific to human PSGL-1 30 ; and DREG-200 (mouse IgG1), specific to human L-selectin 31 have been previously described. The mAb 215 is a mouse IgG2a mAb specific to human PSGL-1 (see Figures   1, 5 , and 6, and data not shown). Anti-CD11a and the PE-conjugated mAbs anti-CD4, CD8, CD19, and CD45RO were purchased from Becton Dickinson (San Jose, CA). A PE-conjugated, anti-CD3 mAb was purchased from Ancell (Bayport, MN). PE-or FITC-conjugated F(ab)'2 goat anti-mouse IgG or IgM were purchased from Jackson Immunoresearch (West Grove, PA). FITC-conjugated, F(ab)'2 goat anti-rat IgM secondary antibody was purchased from Jackson Immunoresearch.
Allophycocyanin (APC)-conjugated streptavidin was purchased from Biogenesis (Kingston, NH).
The horseradish peroxidase-conjugated antibodies, goat anti-mouse IgM and IgG and goat anti-rat IgM were purchased from Pierce (Rockford, IL).
Cells and Transfectants. Peripheral blood was collected from normal healthy donors. These procedures were performed in accordance with a protocol approved by the Institutional Review Board: Human Subjects Committee at the University of Minnesota. Leukocytes were isolated by red blood cell lysis or dextran sedimentation, plus ficoll-hypaque centrifugation to separate mononuclear and polymorphonuclear cells, as previously described 8, 32 . The Chinese hamster ovary (CHO)-dhfr -(ATCC, Manassas, VA) stable transfectants CHO/PSGL-1 and CHO/PSGL-1/FucT-VII/C2GnT were constructed as previously described 12, 33 with minor modifications. Briefly, the human wild-type cDNAs encoding PSGL-1, C2GnT, and FucT-VII were ligated into the expression vectors, pcDNA3.1/Zeocin (Invitrogen, Carlsbad, CA), pcDNA3 (Invitrogen), and pCDM8/puromycin, respectively. The CHO-dhfr -stable transfectants CHO/FucT-VII and CHO/FucT-VII/C2GnT were constructed as previously described 12, 33 . The Jurkat/FucT-VII and Molt-4/FucT-VII stable transfectants were constructed as previously described 34, 35 . Cells were treated with neuraminidase (from Clostridium perfringens, which hydrolyzes α(2-3), α(2-6), or α(2-8) linkages; Roche, Mannheim, Germany) and O-glycoprotease (O-sialoglycoprotein endopeptidase; Accurate Chemical and Scientific Corporation, Westbury, NY) to remove terminal sialic acid moieties and sialomucins, respectively, as previously described [36] [37] [38] .
Immunization and mAb generation. These procedures were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee at the University of only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 6 Minnesota. CHO/PSGL-1/FucT-VII/C2GnT transfectants were used as immunogen for generation of mAb. CHO/PSGL-1/FucT-VII/C2GnT cells (5x10 7 ) were injected intraperitoneally into Balb/c mice at biweekly intervals. The initial injection contained the adjuvant Gerbu (GERBU Biotechnik GmbH, Heidelberg, Germany), whereas subsequent injections did not contain adjuvant. The SP2/0 myeloma cell line was used as a fusion partner, and previously described procedures were followed in the generation of monoclonal hydridomas 38, 39 . All mAbs produced were expanded by in vitro tissue culture procedures. Biotinylation of mAbs was performed using NHS-SS-LC-biotin (Pierce, Rockford, IL), as per manufacturer's instructions. The generated mAb CHO-131 (IgM, kappa light chain) is described in this report.
Preparation of protein-adsorbed 4 µm latex microspheres. Sulfate polystyrene latex microspheres (Interfacial Dynamics, Portland, OR) were adsorbed with human PSGL-1 that was immunoprecipitated from neutrophils. The anti-PSGL-1 mAb PL1 was used to immunoprecipitate PSGL-1, which was done in buffer containing 50 mM n-octyl-β-glucopyranoside. Dilution of the detergent below its critical micelle concentration allowed for PSGL-1 adsorption indicating the importance of the core 2 branch for reactivity. However, other determinants including fucose also appear to compose the CHO-131 epitope since the structure C2-O-sLN was not recognized ( Figure 1B) . To demonstrate that the observed reactivities were not due to differences in glycopeptide coating, the anti-PSGL-1 peptide mAb PL1 was used in the ELISA. PL-1 detected high levels of all four glycopeptides ( Figure 1B) . The specificity of CHO-131 was confirmed by the observation that there was no binding to GP-6', GP-5 and GP-1 even at the highly saturating concentration of 10 µg/ml ( Figure 1C ). CHO-131 also did not stain Jurkat/FucT-VII transfectants greater than an isotype negative control mAb, whereas HECA-452 stained this transfectant at high levels ( Figure 3) . Together, the data above indicate that cell staining by CHO-131 requires, in part, α2,3-sialyltransferase, FucT-VII and C2GnT.
CHO-131 recognizes
Moreover, CHO-131 staining correlated with the expression of P-selectin glycan ligands, whereas the reactivity of anti-sLe X mAbs did not.
CHO-131 primarily binds to sialomucins. C2-O-sLe
X -like structures are common components of sialomucins 15, 47, 48 . Thus, consistent with the specificity of CHO-131, it would be predicted that staining would be affected by the selective removal of cell surface sialomucins using O-glycoprotease. In contrast, the sLe X oligosaccharide is broadly distributed on various cell surface macromolecules and O-glycoprotease treatment has only a modest affect on the overall reactivity by anti-sLe X mAbs 17, 49 . Using flow cytometry, it was observed that CHO-131 and HECA-452 both . Our data together indicates that CHO-131 reactivity requires the functional activity of α2,3-sialyltransferase, FucT-VII, and C2GnT. At this time it cannot be ruled out that CHO-131 also recognizes N-glycans containing β1-6 branches (I-type) terminated with sLe X 27 . However, such a structure would not contribute to CHO-131 staining of human leukocytes since these cells do not express N-glycans with I-type branching 54, 55 .
Expression of the CHO-131 epitope corresponds with the synthesis of P-selectin glycan ligands. For instance, the human hematopoietic cell line Molt-4, but not Jurkat, express P-selectin ligands when transfected with the cDNA for FucT-VII has been reported to block E-selectin binding to purified CLA under shear flow 26 , but has also been used to immunopurify CLA T cells with no blocking effects in assays involving E-and P-selectin 20, 56 . CSLEX-1 has been reported to block neutrophil binding to E-selectin in static assays 57, 58 , whereas HECA-452 and CSLEX-1 ineffectively blocked the binding of T lymphoblasts to E-and Pselectin under shear flow . The differential regulation of particular glycosyltransferases by effector/memory T cells may result in ligands for E-selectin, P-selectin, or both. Based on functional assays, T cell subsets that bind E-selectin or P-selectin have been described 17, 59 .
In summary, the CHO-131 epitope is directly relevant to the expression of high affinity glycan ligands for P-selectin. CHO-131 may then be an important tool for detecting expression of these ligands on specific cells; for instance particular leukocyte subsets or neoplastic cells. only.
